C.S. Mott Children’s Hospital is a leader in treating relapsed and resistant cancers, running Michigan’s largest pipeline of Phase 1 trials and one of the nation’s most advanced gene sequencing programs to deliver personalized therapies. It also operates the state’s largest pediatric bone marrow transplant and cellular therapy programs.
The Chad Carr Pediatric Brain Tumor Center, established in 2018, has become a national hub for high-risk brain tumors. As part of the Pacific Neuro-Oncology Consortium (PNOC) and through sequencing with the MiOncoseq program, the center advances new therapies and shares data internationally via the Children’s Brain Tumor Network.
